Adial Pharmaceuticals ADILW 深 沪
已收盘 07-27 16:00:00 美东时间
0.0009
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0009
- 总市值 1.58万
- 52周最高 0.199
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.0004
- 委 比 0.00%
- 总股本 1750.35万
- 历史最高 2.45
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Adial Pharmaceuticals收涨5.52%，成交额3.13万美元
10月21日，Adial Pharmaceuticals（ADIL）收涨5.52%，报3.82美元，成交额3.13万美元，市值1003.09万美元。 行情数据...
10-21 08:05
Adial Pharmaceuticals Adjourns Meeting Pending Nasdaq Listing
Adial Pharmaceuticals ( ($ADIL) ) has shared an announcement. Adial Pharmaceuti...
10-17 05:51
Adial Pharmaceuticals Adjourns Meeting Pending Nasdaq Listing Decision
Adial Pharmaceuticals ( ($ADIL) ) has issued an announcement. Adial Pharmaceuti...
10-03 04:51
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adial Pharmaceuticals granted a stock option for 155,446 shares with an exercise price of $4.22, vesting over four years. The option was approved as an inducement for employment under Nasdaq rules. The company, now focused on inflammatory diseases, plans to advance AT177, an oral AhR agonist for ulcerative colitis, with IND filing and Phase 1 trials expected in 2027. Forward-looking statements are subject to risks and uncertainties.
09-30 21:46
Adial Pharmaceuticals Amends Agreements to Restore Nasdaq Compliance
Adial Pharmaceuticals ( ($ADIL) ) has shared an update. Adial Pharmaceuticals d...
09-17 05:29
Adial Pharmaceuticals Grants Inducement Stock Options to New Hire
Adial Pharmaceuticals ( ($ADIL) ) just unveiled an update. On August 19, 2026, ...
08-26 04:57
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adial Pharmaceuticals granted a stock option to purchase 307,814 shares at $5.76 per share as an inducement for employment. The option vests over four years and has a ten-year term. The company, focused on developing treatments for inflammatory diseases, recently acquired Azora Therapeutics and is advancing AT177, an AhR agonist for ulcerative colitis. AT177 is in IND-enabling studies, with a Phase 1 trial planned for late 2027.
08-25 20:05
Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge
The latest announcement is out from Adial Pharmaceuticals ( ($ADIL) ). On Augus...
08-22 06:02
Adial Pharmaceuticals shares are trading lower after the company reported a wider net loss for the second quarter.
Adial Pharmaceuticals shares are trading lower after the company reported a wider net loss for the second quarter.
08-18 00:39
Adial Pharmaceuticals Plans Major Leadership and Board Transition
An announcement from Adial Pharmaceuticals ( ($ADIL) ) is now available. As of ...
08-14 05:43
